Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.4K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards tailored and patient-centred care for lentigo maligna.

Clinical and experimental dermatology·2026
Same author

Photoprotective practices in patients with mycosis fungoides: a questionnaire-based survey study.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Comment on 'Context, not class, may be the key signal in systemic JAK inhibitor exposure in MF/SS': reply from authors.

The British journal of dermatology·2026
Same author

Response to Zou et al, "Comment on "Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective multicenter cohort study"".

Journal of the American Academy of Dermatology·2026
Same author

Co-design of a decision aid for the management of lentigo maligna in older and frailer adults.

Skin health and disease·2026
Same author

Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013-2023.

The British journal of dermatology·2026

Related Experiment Video

Updated: Feb 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Anti-PD1/PDL1 induced psoriasis.

Dimitra Voudouri1, Vasiliki Nikolaou1, Konstantinos Laschos2

  • 1Dermato Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, University of Athens, Athens, Greece.

Current Problems in Cancer
|November 4, 2017
PubMed
Summary

Immune checkpoint inhibitors like anti-PD1/PDL1 therapies can trigger psoriasis flares. A family history of psoriasis increases risk, necessitating careful skin monitoring during cancer treatment.

Keywords:
Anti-PD1DurvalumabNivolumabPembrolizumabPsoriasis

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.8K

Related Experiment Videos

Last Updated: Feb 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.8K

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) are crucial for advanced cancers.
  • Immune-related adverse events (irAEs) are common side effects of ICIs.
  • Psoriasis exacerbation is a rare but reported irAE during anti-PD1 therapy.

Purpose of the Study:

  • To describe clinical characteristics of psoriasis exacerbation in patients receiving anti-PD1/PDL1 therapy.
  • To identify risk factors for psoriasis flares during ICI treatment.

Main Methods:

  • Retrospective case series of 5 patients with psoriasis exacerbation.
  • Patients were undergoing treatment with anti-PD1 or anti-PDL1 agents.
  • Clinical data including history, lesion type, and treatment outcomes were analyzed.

Main Results:

  • Five patients (4 male, 1 female; mean age 65.8) with various cancers experienced psoriasis exacerbation.
  • Three patients received anti-PD1 (pembrolizumab, nivolumab) and two received anti-PDL1 (durvalumab).
  • Psoriasis flares occurred after the fourth cycle; 4/5 had guttate lesions. One patient required treatment delay due to severe reaction. Family history was a significant factor.

Conclusions:

  • Both anti-PD1 and anti-PDL1 therapies can induce psoriasis exacerbation, with durvalumab potentially causing more severe flares.
  • Personal and family history of psoriasis are critical risk factors.
  • Close dermatologic monitoring is essential for early diagnosis and management to maintain treatment protocols and patient prognosis.